The UK and US have concluded a important commercial pact that will preserve no duties on British pharmaceutical products entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to raise spending on medicines through the NHS. This commitment ensures that tariffs on these vital goods will stay at nothing for a timeframe of 36 months.
This agreement follows recent warnings to significantly raise duties on patented drug imports, with increases mentioned reaching 100%.
"This arrangement with the UK bolsters the global environment for innovative medicines and brings long-overdue balance to transatlantic drug exports," a release noted.
Economic Importance
Drugs represent one of the Britain's most significant goods shipped to the United States, which is easily the primary destination for large companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months leading up to the third quarter, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of total UK exports in that timeframe.
"This deal safeguards work, increases capital expenditure and paves the way for the UK to establish itself as a international leader for life sciences," a minister commented.
Specific British Pledges
The pact includes several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at fifteen percent. Previously, repayments were more than 20%.
Recent Tensions
This agreement takes place against a ongoing tension between the sector and the UK government over drug pricing and approval rates.
The disagreement were heightened by claims that American customers were charged significantly more for the equivalent treatments than consumers in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or scrapped, while major expansions have been announced toward projects in the United States.
One official publicly accepted that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a share of its total funding over the past decade.
